Acquired thrombotic thrombocytopenic purpura (TTP) is a rare disease in children. Despite advances in diagnosis and treatment, acquired TTP remains a challenging disease due to the lack of a simple diagnostic test and the variable response to plasma exchange. Herein, we describe a case of a 5-year-old of black ethnicity boy who presented with a sudden onset of fatigue and body aches. Laboratory investigations revealed a thrombotic microangiopathic manifestation. TTP was diagnosed, and plasma exchange and corticosteroids were initiated, with an excellent response.
Thrombotic thrombocytopenic purpura (TTP) is a relatively uncommon disorder characterized by the formation of platelet-rich thrombi in the microvasculature. 1 This formation results in consumptive thrombocytopenia, organ ischemia, and increased shear stress (a force causing red blood cell deformation along a plane or planes parallel to the imposed stress in the small blood vessels) with mechanical destruction of the red blood cells (RBCs), resulting in schistocytes. Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa *To whom correspondence should be addressed. elise.schapkaitz@nhls.ac.za TTP is most commonly described in adults in the absence of an underlying cause (idiopathic). TTP also is present secondary to a variety of clinical conditions, such as human immunodeficiency virus (HIV) infection, pregnancy, autoimmune disease, cancer, bone marrow and solid organ transplants, and usage of certain drugs. 3 TTP is rarely diagnosed in childhood and it is often difficult to distinguish from more common thrombotic microangiopathies (TMAs), such as hemolytic uremic syndrome (HUS). It is regarded as a hematological emergency due to the high mortality rate-nearly 90% in untreated cases. 4, 5 Urgent initiation of plasma exchange (PEX) is critical and directly correlates with overall survival. 5 In the past decade, the identification of reduced disintegrin and metalloprotease with thrombospodin-2-like repeats (ADAMTS-13), a protease responsible for the cleavage of von Willebrand factor (vWF), has allowed for improved diagnosis and management of TTP. 6 A severe deficiency (<5%) of ADAMTS-13 activity is found in patients with congenital TTP with inherited mutations (UpshawSchulman syndrome), whereas ADAMTS-13 antibodies and decreased ADAMTS-13 activity (<10%) are detected in acquired TTP.
In Southern Africa, acquired TTP is most frequently secondary to HIV in adults, in contrast to the developed world.
In HIV-associated TTP, endothelial-cell injury plays a major role in the pathogenesis as a result of direct viral invasion of the endothelial cells or indirectly from the effect of inflammatory cytokines. This results in a procoagulant switch, which triggers platelet aggregation and thrombus formation. As such, ADAMTS-13 deficiency has not consistently been identified in HIV-associated TTP. 8 Adjunctive highly active antiretroviral therapy (HAART) is essential in the management of HIV-associated TTP, to downregulate the inflammatory response. 9 HIV-associated TTP in children represents a diagnostic challenge due to low incidence and the less-frequent finding of severely decreased ADAMTS-13 activity. 8 Herein, we describe a case report of TTP as the initial presentation of HIV in a 5-year-old boy.
Case Report
A 5-year-old boy presented to the pediatric oncology and hematology clinic with a sudden onset of fatigue and body aches. His past medical history was insignificant, and there was no family history of hematologic disorders. On arrival, he was lethargic, with an episode of vomiting but no diarrhea.
On examination he was apyrexial, with severe pallor, mild jaundice, cervical and axillary lymphadenopathy and frank hematuria. His neurological examination results were normal, and his weight and height were appropriate for his age, as plotted on World Health Organization (WHO) growth charts.
A . All other causes of TMA were excluded, and a diagnosis of TTP was made. The ADAMTS-13 activity level of 32% (40% to 130%) was not available at diagnosis.
Image 1
Peripheral blood stained with May-Grünwald Giemsa (magnification ×500) from our patient, a 5-year-old boy. Image from the peripheral blood smear at presentation showing marked anisopoikilocytosis, red blood cell (RBC) fragments (arrows), microspherocytes, polychromasia, nucleated RBCs, and severely reduced platelets.
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The patient was started on daily plasma exchange (PEX) at a volume of 1:1 for 10 days ( Table 1) 
Discussion
Historically, a set of 5 diagnostic symptoms was recognized as defining TTP, namely, fever, renal and neurological abnormalities, TMA, and thrombocytopenia. 10 In clinical practice, however, this case contributes to the evidence that TTP should be suspected in patients with severe thrombocytopenia, schistocytes greater than 1% on PBS, and an elevated LDH level in the absence of another cause. 4 Severe renal failure at presentation usually suggests the diagnosis of HUS.
ADAMTS-13 assays are helpful for diagnosis and monitoring the efficacy of PEX; however, testing is only performed by specialized reference laboratories. 11 As such, the diagnosis could not be initially confirmed in this patient. Further, this assay is neither sensitive nor specific for the diagnosis of HIV-associated TTP. Moderately reduced ADAMTS-13 has also been reported in HUS, sepsis, disseminated intravascular coagulopathy, liver disease, and malaria. 12 Thus, for the diagnosis of acute HIV-associated TTP, assays for ADAMTS-13 activity or antibodies are not essential for diagnosis, and PEX should not be delayed.
TTP has been described as a feature of advanced HIV associated with CD4 cell counts of less than 200 × 10 9 per μL and high viral loads in HAART-naïve patients. 13, 14 This may partly explain the heterogeneity in the clinical presentation and the variability in response to therapy. Patients with virological suppression are more likely to achieve stable remission. 15 Thus, adjunctive HAART and adherence monitoring are essential to the management of HIV-associated TTP. 15 The role of maintenance therapy has not been established in TTP, despite the high risk of relapse within the first 2 years after treatment completion. The high mortality rate reported in TTP emphasizes the importance of early intervention. Current guidelines recommend PEX as the standard of care. 11 The rationale for using PEX is to replace ADAMTS-13 and to remove the ultralarge VWF multimers (monomeric subunits). The optimal duration varies per individual, which raises concern regarding the cost of TTP management in developing countries.
Initially, this patient was supported with plasma infusion because he was referred on a weekend. Plasma infusion alone is considered inferior to PEX. 4 However, a previous South African study 14 demonstrated the importance of plasma infusions when PEX is not easily accessible. Also, corticosteroids were administered to the patient. The efficacy of this regimen remains unclear, particularly in the absence of routine ADAMTS-13 testing. 16 The patient showed a good response to PEX and corticosteroids. HAART was initiated in the hospital, and the outcome for the patient to date has been favorable.
Conclusion
This case report emphasizes that clinicians need to consider the rare hematological emergency of TTP in children, to expedite early referral to a pediatric hematology unit when necessary. HIV-associated TTP remains a diagnostic challenge; information on ADAMTS13 activity and antibody assays are not readily available and when they are, the results often are not supportive of the diagnosis. Thus, in the appropriate clinical context, the diagnosis of HIV-associated TTP should be considered on the basis of surrogate laboratory markers, namely, severe thrombocytopenia, significant RBC fragments, and elevated LDH levels. PEX and adjunctive HAART are essential to the management of TTP and have dramatically improved patient outcome. LM
